Santen Pharmaceutical Co., Ltd. (TYO:4536)
2,056.00
-7.00 (-0.34%)
Nov 18, 2026, 3:30 PM JST
Santen Pharmaceutical Revenue
Santen Pharmaceutical had revenue of 74.33B JPY in the quarter ending September 30, 2026, with 7.51% growth. This brings the company's total for the last twelve months to 297.03B, up 1.91% year-over-year. In the fiscal year ending March 31, 2026, Santen Pharmaceutical had annual revenue of 291.62B, down -2.79%. That makes Santen Pharmaceutical the 5,226th largest company in the world by revenue and 534th in Japan.
Revenue (ttm)
297.03B
Revenue Growth
+1.91%
P/S Ratio
2.23
Revenue / Employee
74.86M
Employees
3,968
Market Cap
661.58B
Revenue by Geography
- Japan 146.81B 50.3%
- Europe, Middle East and Africa (EMEA) 80.10B 27.5%
- Asia (Exclude China) 33.25B 11.4%
- China 30.01B 10.3%
- Others 1.45B 0.5%
Fiscal year ended Mar 31, 2026 See the full Santen Pharmaceutical breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 291.62B | -8.38B | -2.79% |
| Mar 31, 2025 | 300.00B | -1.96B | -0.65% |
| Mar 31, 2024 | 301.97B | 22.93B | 8.22% |
| Mar 31, 2023 | 279.04B | 12.78B | 4.80% |
| Mar 31, 2022 | 266.26B | 16.65B | 6.67% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 4.69T |
| MediPal Holdings | 3.89T |
| Alfresa Holdings | 3.16T |
| Otsuka Holdings | 2.69T |
| Chugai Pharmaceutical | 1.41T |
| COSMOS Pharmaceutical | 1.11T |
| Sugi Holdings | 1.05T |
| HOYA Corporation | 1.01T |
Santen Pharmaceutical News
- 13 days ago - Santen Pharmaceutical Quarterly report: Q2 2027 - Filings
- 13 days ago - Santen Pharmaceutical Slides: Q2 2027 - Filings
- 8 months ago - Santen Pharmaceutical Slides: FY 2026 - Filings
- 3 years ago - Santen Pharmaceutical upgraded to Buy from Neutral at Citi - TheFly